CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

CCRM and its contract development and manufacturing organization OmniaBio announced a partnership with Avectas Limited on June 15, 2026, to assess Avectas’ automated cell therapy manufacturing platform. The goal is to improve scalability, automation, and cost-effective production for CCRM’s global network, which currently includes hubs in Canada, Australia, and the Nordic countries. OmniaBio’s AI-enabled Intelligent Factory aims to streamline workflows, while Avectas’ platform addresses challenges in scale-up and automation, critical for expanding patient access to therapies. The collaboration follows CCRM’s recent Memorandum of Understanding with Ireland’s RINN Advanced Therapies to establish CCRM Ireland, bolstering advanced therapy capabilities in the region. Dr. Michael May, President and CEO of CCRM, highlighted the potential of Avectas’ platform to enhance automation and efficiency, supporting regional manufacturing. Dr. Michael Maguire, CEO of Avectas, emphasized the significance of the partnership amid growing life sciences collaboration between Canada and Ireland, including government-backed initiatives. CCRM operates as a public-private partnership funded by the Canadian and Ontario governments, focusing on regenerative medicine and cell/gene therapies. Its hub-and-spoke model combines centralized and distributed manufacturing, while Avectas’ platform aligns with these efforts by addressing key bottlenecks in production. The partnership underscores a broader push to make advanced therapies more accessible globally, leveraging technology and regional infrastructure.